Following series C financing, Beijing Health Guard Biotechnology Inc. (thereafter, the Company), in accordance with its overall financing needs and capital plan, closed a CNY 1.015 billion pre-IPO round. More than ten institutional investors specializing in the healthcare sector participated in the pre-IPO round, including CCB International, Yunfeng Capital, Jemicare, Yingke PE, Oriental Fortune Capital, High Capital, and Hong Yin Capital.

Proceeds from this round will be used to fund clinical trials of the Recombinant trivalent HPV vaccine (targeting HPV 16/18/58) and Recombinant nonavalent HPV vaccine (targeting HPV 6/11/16/18/31/33/45/52/58 and expressed in E. coli), construction of Kunming commercial production plant, pre-clinical and clinical studies of a Recombinant norovirus vaccine and a Recombinant COVID-19 vaccine, and R&D efforts for other discovery projects, as well as to supplement working capital.

Over the years, the Company has been committed to helping improve public health and regards unmet clinical needs as its overarching guiding principle for product design and pipeline expansion. We aim to develop innovative and advanced vaccines to protect the public from the threat of infectious diseases.

During R&D, the Company never readily drifts with the current or boasts of its accomplishments. Instead, it employs a scientific, rigorous, pragmatic and sustainable approach, which enables the Company to win over the government, industry, investors and capital market. Moreover, the Company’s R&D platform starts to stand out, gradually reinforcing the core strengths of the Company. In the future, with greater support from the capital market, the Company will develop and move more innovative vaccines into clinical studies and commmercial production.